Positive Phase II trial with Evaxion’s personalized cancer vaccine EVX-01 - The Pharma Letter
Evaxion (Nasdaq: EVAX) reported three-year follow-up from its Phase II trial of personalized cancer vaccine EVX-01 in advanced melanoma: all patients maintained the clinical responses observed at two years, with no tumor progression, and received EVX-01 as stand-alone therapy in the third year. Shares rose 5.5% to $2.99 in pre-market trading on the news. For a techbio whose vaccines come off its AI-Immunology platform, extended response durability without progression is the key evidence point that its AI-selected antigens translate into lasting clinical benefit, and stand-alone activity in year three strengthens the case beyond earlier-trial contexts.